Ototoxic Medication Stewardship in Clinical Otolaryngology

Abstract

Ototoxicity remains a significant iatrogenic complication in clinical otolaryngology, with a broad array of therapeutic agents implicated in sensorineural hearing loss and vestibular dysfunction. This review synthesizes current evidence regarding the burden, mechanisms, risk stratification, diagnostic approaches, management strategies, and stewardship principles for ototoxic medications, offering guidance for clinicians to optimize patient safety and outcomes.

Introduction

Ototoxicity describes the pharmacologically-induced damage to the cochlear and vestibular apparatus, leading to hearing loss, tinnitus, and balance disorders. The expanding therapeutic arsenal in modern medicine has increased the incidence and recognition of drug-induced otologic sequelae. While life-saving or indispensable in certain contexts, ototoxic agents demand vigilance, risk mitigation, and judicious prescribing. Otolaryngologists, audiologists, and multidisciplinary teams play a crucial role in the stewardship of these medications to minimize irreversible morbidity.

Epidemiology / Disease Burden

The true incidence of ototoxicity is variably reported, with estimates ranging from 2% to 33% in patients receiving high-risk medications such as aminoglycosides or platinum-based chemotherapies. Pediatric, elderly, and critically ill populations are disproportionately affected. Ototoxicity is a leading cause of acquired sensorineural hearing loss worldwide, contributing to communication impairment, social isolation, and reduced quality of life. Epidemiologic trends highlight the need for robust surveillance and preventive strategies in otolaryngology practice.

Pathophysiology

Ototoxic agents predominantly target the hair cells of the cochlea and vestibule. Aminoglycosides induce free radical formation and mitochondrial dysfunction leading to apoptosis, particularly in outer hair cells and the stria vascularis. Platinum compounds form DNA adducts, disrupt cellular metabolism, and interfere with cochlear microcirculation. Loop diuretics and antimalarials act via electrolyte imbalance and direct cytotoxicity. Genetic susceptibility, including mitochondrial mutations (e.g., m.1555A>G), modulates individual vulnerability to ototoxic insults. The cumulative dose, administration route, and pharmacokinetic properties further influence risk profiles.

Risk Factors

Major risk factors for ototoxicity include pre-existing sensorineural hearing loss, renal impairment, concomitant use of multiple ototoxic drugs, prolonged exposure, advanced age, and genetic predispositions. Critically ill patients, those undergoing cancer chemotherapy, and neonates in intensive care are especially vulnerable. Awareness and early identification of these risk factors underpin effective ototoxic medication stewardship.

Clinical Features

Ototoxicity typically manifests as bilateral, symmetrical, high-frequency sensorineural hearing loss, which may progress to involve lower frequencies and speech discrimination. Tinnitus, vertigo, and disequilibrium are common but often underreported. In pediatric populations, symptoms may be subtle, presenting as delayed speech or inattentiveness. Early detection is challenged by the insidious and often subclinical onset of auditory and vestibular dysfunction.

Diagnosis

Baseline and serial audiologic monitoring are central to the diagnosis of ototoxicity. High-frequency pure-tone audiometry, otoacoustic emissions, and speech discrimination tests are sensitive modalities. Vestibular assessment may include videonystagmography and dynamic posturography. Biomarkers such as plasma drug levels, when available, can aid in risk assessment. Comprehensive documentation and interdisciplinary communication ensure timely intervention and accurate attribution of causality.

Treatment & Management

Management prioritizes prompt cessation or substitution of the offending agent whenever feasible. Dose adjustment and alternative therapies should be considered, especially in high-risk individuals. Adjunctive measures include antioxidant supplementation, adequate hydration, and renal function optimization. Audiologic rehabilitation, including hearing aids and cochlear implants, may be indicated for persistent deficits. Multidisciplinary collaboration facilitates individualized care plans that balance therapeutic efficacy with otologic safety.

Recent Advances / Emerging Therapies

Recent research explores pharmacogenomic screening for susceptibility alleles, targeted drug delivery systems to minimize cochlear exposure, and otoprotective agents such as sodium thiosulfate and N-acetylcysteine. Novel monitoring protocols leveraging portable audiometry and telemedicine are improving early detection. Ongoing clinical trials are assessing new agents with reduced ototoxic potential and strategies to regenerate cochlear hair cells following injury.

Guideline Recommendations

Professional societies advocate for baseline and serial audiometric testing in all patients receiving high-risk ototoxic medications. Individualized risk-benefit assessment, patient education on symptom recognition, and shared decision-making are integral components. Guidelines recommend genetic screening in select populations and emphasize the importance of documentation, reporting, and pharmacovigilance. Multidisciplinary stewardship programs are encouraged to standardize practices and improve outcomes.

Conclusion

Ototoxic medication stewardship is a critical aspect of contemporary otolaryngology, mandating vigilance, risk stratification, and evidence-based management. Integrating recent advances, guideline-driven monitoring, and patient-centered approaches can substantially mitigate the burden of drug-induced otologic dysfunction. Continued research and interdisciplinary collaboration will be essential to refine preventive strategies and enhance the quality of care for at-risk populations.